GLP-1 Digest: Latest Research and Clinical Updates April 22, 2026
This digest reviews GLP-1 receptor agonist clinical evidence April 2026, highlighting cardiovascular outcomes and safety profiles. It includes comparative efficacy data for agents like semaglutide and tirzepatide. Emerging clinical insights and…
Your Body Fights Back, But Your Doctor Has Options
Clinical Takeaway GLP-1 plateaus happen because the body adapts by slowing metabolism and increasing hunger signals over time. Clinicians may adjust dosing, add adjunct therapies, or address behavioral factors to push past the stall. Your Body Fights…
Same Drug, Different Goals: GLP-1s Treat More Than Sugar
Clinical Takeaway GLP-1 medications like semaglutide are FDA-approved for both type 2 diabetes management and chronic weight loss, but the target doses, titration schedules, and treatment goals can differ significantly between the two indications. Talk…
Endocannabinoid System & GLP-1 Receptor Mental Health Research
GLP-1 receptor agonists mental health research investigates the drug class's effects on common mental illnesses using genetic methods. This research helps clarify whether these medications influence mental illness risk. Findings suggest potential…
GLP-1 Digest: Latest Research and Clinical Updates April 17,
This issue reviews GLP-1 receptor agonist discontinuation evidence and its impact on obesity treatment outcomes. It highlights musculoskeletal risks and cardiovascular benefits linked to these therapies. Emerging genetic data further inform personalized…
GLP-1 Weekly Roundup April 16, 2026: Liver Benefits and Research
New research highlights GLP-1 receptor agonist liver benefits alongside diabetes prevention with metformin. Genetic predictors of weight loss response enhance personalized treatment. This April 2026 roundup covers key clinical evidence for GLP-1…
GLP-1 Digest: Latest Research and Clinical Updates April 16,
This issue highlights GLP-1 receptor agonists liver benefits with new research supporting their role in metabolic medicine. Genetic predictors of treatment response and metformin's role in insulin resistance are also discussed. These findings offer…
GLP-1 Policy Watch: Insurance, Compounding, and FDA Updates
The GLP-1 insurance coverage update highlights key policy developments impacting clinical prescribing and patient access. Twelve states mandate coverage for obesity, but restrictions remain. Clinicians must verify formulary status to navigate insurance…
Semaglutide Weight Management Medicine: Ozempic vs Wegovy
Semaglutide weight loss varies significantly between Ozempic and Wegovy due to different dosing regimens. Wegovy’s higher dose is specifically approved for chronic weight management, producing greater weight reduction. Understanding these differences…
Understanding Pharmacogenomic Predictors of GLP-1 Response
Pharmacogenomic predictors GLP-1 response help explain individual differences in weight loss and side effects with GLP-1 receptor agonists. Genetic markers can guide personalized prescribing. This approach aims to improve treatment outcomes and…
